Welcome!

News Feed Item

Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"

MOUNTAIN VIEW, CA -- (Marketwired) -- 07/23/14 -- Amunix Operating Inc., a biotechnology company developing hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules, said its research paper, "Multivalent Antiviral XTEN-Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility" is now available online (http://pubs.acs.org/doi/abs/10.1021/bc500215m) and will be published in an upcoming issue of "Bioconjugate Chemistry." The paper presents positive in vivo data demonstrating the feasibility and versatility of multivalent drug display through XTENylation using the approved anti-HIV drug T-20 (enfuvirtide or Fuzeon) as a model therapeutic payload.

XTEN, a protein-based polymer that mimics the biophysical properties of PEG, has been used to extend the half-life of genetically fused therapeutic proteins and peptides. To expand the applications of XTEN technology to half-life extension of other classes of molecules, XTEN protein polymers and methods for chemical XTENylation were developed. Monovalent, multivalent and bispecific XTEN conjugates with various payloads have been synthesized and tested for their biological activities. XTEN is easily metabolized, thereby eliminating the risk of tissue accumulation. Single or multiple payloads can be conjugated or genetically fused to XTEN, which allows the generation of monospecific, bispecific, as well as multivalent biopharmaceuticals.

In its recently published paper, Amunix described the use of its proprietary XTEN technology to develop a versatile platform for the multivalent delivery of an antiviral peptide. As a genetically defined protein polymer, XTEN facilitates the incorporation of multiple copies of a drug at precisely specified positions along its length. The company used the approved anti-HIV drug T-20 as a model therapeutic peptide and conjugated it to XTEN in a number of formats to test the effects of drug valency and spacing on the antiviral activity of the conjugates. PolyPeptide Group, a custom peptide synthesis group, synthesized the peptide for Amunix, provided valuable input on the experiment design and co-authored the manuscript.

Volker Schellenberger, PhD, Amunix President and Chief Executive Officer, said, "Conjugation of T-20 to XTEN was found to greatly extend the in vivo half-life of the peptide in rats, and it was possible to tune the in vitro potency of the conjugates by varying the copy number and spacing of the peptides on XTEN. T-20 was also found to exhibit greatly enhanced solubility upon conjugation to XTEN. Based on these results, we believe that XTEN constitutes a promising platform for the discovery and characterization of a new class of 'biobetter' therapeutics and offers significant advantages for the development of these drugs."

About Amunix
Amunix Operating Inc., a biotechnology company headquartered in Mountain View, CA, has developed a novel half-life extension technology based on XTEN; hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically conjugated to other peptides, proteins and small molecules. Through this proprietary XTEN technology, the company creates and develops novel versions of clinically-proven pharmaceutical products that may offer better efficacy, safety and dosing frequency by extension of the half-life. One XTEN product, Exenatide-XTEN (VRS-859), has completed a Phase I study through Amunix partner Diartis. Amunix partner Versartis recently completed a Phase 2a clinical trial evaluating weekly, semi-monthly and monthly dosing regimens of hGH-XTEN (VRS-317) in children with growth hormone deficiency. In addition, through its partnership with Biogen Idec, Amunix is developing Factor VIII and is working with Janssen Biotech, Inc. and its affiliates to apply the XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen. Amunix has several other undisclosed partners in various therapeutic areas. Founded in 2006, Amunix is a profitable, independent biotechnology company with no external investors. Amunix is actively seeking partnerships for application of its XTEN technology for half-life extension or tumor drug delivery. For additional information about the company, please visit www.amunix.com.

About PolyPeptide
The PolyPeptide Group, with sites in Denmark, France, India, Sweden and the USA, is one of the world's leading independent contract manufacturers of therapeutic peptides. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture. For additional information about the company, please visit www.polypeptide.com.

PLEASE NOTE: Research reported in this press release was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R43AI102765. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Amunix Media Contact:
Debra Catz Bannister
Email Contact
530 676-7373

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across supply chain networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost and time for product recall as well as advance trade. Are you curious about Blockchain and how it can provide you with new opportunities for innovation and growth? In her session at 20th Cloud Exp...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
As pervasive as cloud technology is -- and as persuasive as the arguments are for using it -- the cloud has its limits. Some companies will always have security concerns about storing data in the cloud and certain high-transaction applications will always be better suited for on-premises storage. Those statements were among the bottom-line takeaways delivered at Cloud Expo this week, a three day, bi-annual event focused on cloud technologies, adoption and associated challenges.
SYS-CON Events announced today that Hitachi, the leading provider the Internet of Things and Digital Transformation, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Hitachi Data Systems, a wholly owned subsidiary of Hitachi, Ltd., offers an integrated portfolio of services and solutions that enable digital transformation through enhanced data management, governance, mobility and analytics. We help globa...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.